Compounded DHEA Troches: A Prescriber's Guide
DHEA is sold over the counter as a dietary supplement, compounded as a prescription troche, and FDA approved as a vaginal insert, all at the same time, under three different regulatory tracks. This guide separates the three, explains why the troche route exists, and covers what compounding can and cannot claim.
What DHEA is
DHEA, dehydroepiandrosterone, is a steroid hormone produced by the adrenal glands and, in smaller amounts, the gonads and brain. It is a precursor, meaning the body converts it into other hormones, including testosterone and estrogens, in peripheral tissue.
Adrenal DHEA production declines steadily with age, which is the basis for most compounded DHEA prescriptions. Whether restoring DHEA levels produces a clinical benefit is a separate question from whether levels decline, and the two get conflated constantly in marketing for this hormone.
Three regulatory tracks, one molecule
The same DHEA molecule sits on three different regulatory tracks in the United States, and confusing them is the single most common mistake in how this hormone gets discussed.
| Form | Regulatory track | What that means |
|---|---|---|
| Over the counter capsules | Dietary Supplement Health and Education Act | Regulated as a supplement, not evaluated by FDA for safety or efficacy the way a drug is |
| Compounded troche, capsule or cream | Section 503A | Prepared by a licensed pharmacy under a valid prescription, not FDA approved |
| Prasterone vaginal insert (brand Intrarosa) | FDA approved new drug | Approved for moderate to severe dyspareunia due to menopause, reviewed for safety and efficacy for that indication |
Prasterone is the pharmaceutical name for DHEA when used as a drug substance. Its FDA approval is also the legal hook that makes DHEA eligible for compounding under 503A, since bulk drug substances qualify when they are a component of an already approved drug product, and DHEA also carries a USP or NF monograph.
Eligible to compound is not the same as approved for the use being compounded. The vaginal insert is approved specifically for dyspareunia. A compounded oral troche for general hormone support runs on a completely separate, unapproved basis, even though both trace back to the same molecule and the same underlying eligibility.
Why a troche instead of a capsule
Oral DHEA has low bioavailability, generally cited at under 10 percent, because a large portion is converted to inactive DHEA sulfate during first pass metabolism in the gut and liver. That single fact is the entire rationale for the troche route.
A troche dissolves in the mouth and is intended to absorb across the buccal or sublingual mucosa, entering circulation directly rather than travelling through the gut and liver first. That is the same first pass avoidance logic used for other compounded troches, covered in more depth in our guide to how troches work as a dosage form.
Transdermal and percutaneous DHEA, delivered as a cream or gel, is a separate route with its own published pharmacokinetic data showing higher bioavailability than oral capsules. Vaginal DHEA, the approved prasterone insert, is a third route entirely, intended for local action with limited systemic absorption.
What the evidence actually shows
There is no published pharmacokinetic study of a compounded DHEA troche specifically. That needs to be stated plainly rather than implied away.
What does exist: a randomized study comparing oral capsules, transdermal gel and transdermal cream found that percutaneous administration avoided the heavy conversion to DHEA sulfate seen with the oral route, while metabolite patterns stayed broadly similar across routes. Separate randomized trials of intravaginal DHEA suppositories, the work that ultimately supported prasterone's approval, measured systemic DHEA and DHEA sulfate levels at several concentrations and found they generally stayed within the normal premenopausal range.
On broader clinical benefit, DHEA has been studied for mild to moderate major depressive disorder, and Canadian clinical guidance lists it as an option based on limited trial evidence, with significant heterogeneity noted between studies. That is the strongest published clinical signal for DHEA generally, and it does not concern the troche form or the uses this hormone is most often compounded for.
The rationale for a troche is pharmacologic reasoning about first pass metabolism, borrowed from how other steroid troches behave, not a DHEA specific trial. Nothing here claims a compounded DHEA troche treats aging, restores vitality, or improves any outcome. The prescriber determines whether DHEA and this route are appropriate for an individual patient.
Not to be confused with 7 keto DHEA
7 keto DHEA is a different, related molecule, and FDA has specifically weighed it against inclusion on the 503A bulks list. The two get mixed up in search and in marketing, so it is worth separating them here.
7 keto DHEA is a metabolite of DHEA that does not convert to testosterone or estrogen the way DHEA does. In a proposed rule addressing bulk drug substances evaluated for the 503A list, FDA weighed 7 keto DHEA's physicochemical characteristics, safety, effectiveness and historical use, and proposed against including it on the list. That is a separate finding from DHEA itself, which remains compoundable through the component and monograph pathway described above.
The FDA approved DHEA product
Prasterone, brand name Intrarosa, is an FDA approved vaginal insert for moderate to severe dyspareunia, a symptom of vulvovaginal atrophy due to menopause. Where that specific indication applies, the approved product is generally the appropriate first choice.
Compounding becomes relevant when a prescriber wants a route, strength or combination that the approved insert does not offer, such as a sublingual troche for a different indication, or a strength between what is commercially available.
Question about DHEA strength, route or combining it with another hormone?
Call (909) 378-7301Side effects and monitoring
Because DHEA converts to testosterone and estrogens, its side effect profile follows from those downstream hormones as much as from DHEA itself.
Androgenic effects have been reported, including acne, oily skin and unwanted hair growth, more often in women. Because DHEA can raise estrogen and androgen levels, it carries theoretical concerns in hormone sensitive cancers, and prescribers generally avoid it in patients with a history of breast, ovarian, uterine or prostate cancer. Mood changes, insomnia and menstrual irregularity have also been reported. DHEA can interact with hormone therapies and with medications metabolized through related pathways. This list is not complete. The prescriber determines suitability and any monitoring, and patients should report new symptoms rather than adjusting a dose on their own.
Writing the prescription
State the strength per troche, the quantity, placement and any combination hormones. Troches can be scored for titration if you expect to adjust the dose over time.
- Write the strength of DHEA per troche and the number of troches to dispense.
- State buccal or sublingual placement and frequency in the directions.
- Note any combination actives, such as pregnenolone or other hormones, and the base preference or pharmacist's choice.
- Call (909) 378-7301 to confirm the formulation and current turnaround time.
Serving prescribers in California
Mixwell Compounding Pharmacy is a PCCA member pharmacy in Chino, CA, performing non sterile compounding only. We work with prescribers across the Inland Empire, Los Angeles County and Orange County, and deliver across California.
- Chino
- Chino Hills
- Ontario
- Rancho Cucamonga
- Upland
- Pomona
- Diamond Bar
- Corona
- Riverside
- Eastvale
- Brea
- Fullerton
Common questions
Is compounded DHEA legal?
Yes, DHEA is eligible for compounding under Section 503A because it is a component of prasterone, an FDA approved drug, and it also carries a USP or NF monograph. A compounded DHEA troche is not itself FDA approved and is prepared only under a valid, patient specific prescription.
Is compounded DHEA the same as the DHEA sold over the counter?
The molecule is the same, but the regulatory paths are different. Over the counter DHEA is a dietary supplement under DSHEA, not evaluated by FDA for safety or efficacy as a drug. Compounded DHEA is a prescription preparation made under Section 503A.
Why is DHEA compounded as a troche instead of a capsule?
Oral DHEA has low bioavailability, generally cited under 10 percent, because a large portion converts to inactive DHEA sulfate during first pass metabolism. A troche is intended to absorb across the mouth, entering circulation directly, using the same rationale applied to other compounded troches.
Is there a trial proving DHEA troches work?
No troche specific pharmacokinetic or clinical trial has been published. The rationale is pharmacologic reasoning about first pass metabolism, not a DHEA troche trial. Published data covers oral capsules, transdermal preparations and vaginal suppositories.
Is DHEA the same as 7 keto DHEA?
No. 7 keto DHEA is a related but distinct metabolite that does not convert to testosterone or estrogen. FDA has proposed against including 7 keto DHEA on the 503A bulks list, a separate finding from DHEA itself, which remains compoundable through the component and monograph pathway.
Is there an FDA approved DHEA product?
Yes, prasterone, brand name Intrarosa, an FDA approved vaginal insert for moderate to severe dyspareunia due to menopause. It is approved for that specific indication, not for oral or sublingual use.
Does Mixwell accept insurance?
Mixwell does not accept insurance. Call (909) 378-7301 to discuss current pricing.
Key Takeaways
- DHEA sits on three separate regulatory tracks at once: dietary supplement, compounded prescription, and the FDA approved vaginal insert prasterone.
- DHEA qualifies for 503A compounding because it is a component of prasterone and carries a USP or NF monograph, which is a legal eligibility, not an approval for oral or sublingual use.
- The troche route exists because oral DHEA bioavailability is under 10 percent due to first pass metabolism, reasoning borrowed from other troches rather than a DHEA troche specific trial.
- 7 keto DHEA is a different molecule that FDA has proposed against including on the 503A bulks list, and should not be confused with DHEA itself.
- Compounded DHEA troches are not FDA approved, side effects follow from DHEA's conversion to testosterone and estrogen, and a valid prescription is required.
Sources
- U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. fda.gov
- Amendments to the List of Bulk Drug Substances That Can Be Used to Compound Drug Products in Accordance With Section 503A, including evaluation of 7 keto DHEA. Federal Register, 2019. federalregister.gov
- Bioavailability and metabolism of oral and percutaneous dehydroepiandrosterone in postmenopausal women. Journal of Steroid Biochemistry and Molecular Biology. sciencedirect.com
- DHEA bioavailability following administration of vaginal suppositories in postmenopausal women, Phase I randomized, placebo controlled study, cited in prasterone patent documentation.
- Dehydroepiandrosterone, uses and clinical evidence summary, including CANMAT guideline reference for major depressive disorder. drugs.com
- U.S. Food and Drug Administration. Prasterone (Intrarosa) prescribing information.
- U.S. Food and Drug Administration. Compounding and the FD&C Act, Section 503A.